TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03754322

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Microscopy/RDT
Description: Standard of care management of malaria in pregnancy relies on microscopy and/or RDT for diagnosis
Study: NCT05582785

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperfine MRI
Description: Patients who have a standard of care MRI, CT or US will undergo a low-field MRI utilizing Hyperfine either at the patient's bedside or in the department of Radiology. Results of the Hyperfine MRI will not be used for clinical care and will only be available to members of the research team for review.
Study: NCT06241755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG for Therapeutic Use
Description: Specification: 60 mg (6.0×10\^7 CFU)/vial, each vial contains BCG 60 mg and each mg BCG shall have a count of live bacteria not less than 1.0×10\^6 CFU.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG for Therapeutic Use
Description: Specification: 60 mg (6.0×10\^7 CFU)/vial, each vial contains BCG 60 mg and each mg BCG shall have a count of live bacteria not less than 1.0×10\^6 CFU.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG for Therapeutic Use
Description: Specification: 60 mg/vial with a count of live BCG bacteria not less than 1.0×10\^6 CFU/mg.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG for Therapeutic Use
Description: Specification: 60 mg/vial with a count of live BCG bacteria not less than 1.0×10\^6 CFU/mg.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h.
Study: NCT05879679

Intervention type: BEHAVIORAL
Intervention: Food craving induction
Description: Standardized craving induction procedure will be used, based on exposure to food-related images (https://www.lippc2s.fr/food-cal-pictures/). Craving intensity will be measured by visual analogic scale before and after the induction sequence.

Intervention type: BEHAVIORAL
Intervention: Food craving induction
Description: Standardized craving induction procedure will be used, based on exposure to food-related images (https://www.lippc2s.fr/food-cal-pictures/). Craving intensity will be measured by visual analogic scale before and after the induction sequence.
Study: NCT06216470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 is a human monoclonal antibody that binds the antigenic loop present in all forms of the surface envelope protein (small, middle, and large HBsAg).
Study: NCT04813016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramal 1
Description: Early intraperitoneal injection of tramal and bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramal 1
Description: Early intraperitoneal injection of tramal and bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramal 2
Description: Late intraperitoneal injection of tramal and bupivacaine
Study: NCT05345977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eMotiph
Description: Mobile application for patients with schizophrenia.
Study: NCT04813016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramal 2
Description: Late intraperitoneal injection of tramal and bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramal 2
Description: Late intraperitoneal injection of tramal and bupivacaine
Study: NCT04764279

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OPTIFAST dietary supplement
Description: Participants will use Optifast Nutrition Supplement as previously described
Study: NCT06161870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: individualized vancomycin dosing based on the population pharmacokinetics (PK) model
Description: The experimental group will be guided at the bedside with individualized vancomycin dosing by a drug dosimetry software tool that incorporates a PK model developed by Roberts JA et al. for data from sepsis patients. The model developed by Roberts JA et al. has been validated in multiple centers to have a good ability to predict the concentration-time data of patients. Once the basic information of participants such as gender, age, body weight, and creatinine clearance rate (CCR) is entered, the software tool can calculate the dosing regimen that is estimated to achieve the pharmacodynamic (PD) target. The area under the curve (AUC24) of 400-600mg·h/L is identified as the PD target of vancomycin.

Intervention type: DRUG
Group type: OTHER
Intervention: empirical vancomycin dosing
Description: The control group will be administered empirically (15-20 mg/kg vancomycin infused intermittently every 8-12 hours depending on the actual body weight of participants).
Study: NCT04997083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary Expander with Differential Opening (EDO)
Description: The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Petit face mask
Description: The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion. It consists of forehead cap, chin cap, and cross bar.
Study: NCT04813016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 1
Description: Early intraperitoneal injection of dexmedetomidine and bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 1
Description: Early intraperitoneal injection of dexmedetomidine and bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 1
Description: Early intraperitoneal injection of dexmedetomidine and bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 2
Description: Late intraperitoneal injection of dexmedetomedine and bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 2
Description: Late intraperitoneal injection of dexmedetomedine and bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 2
Description: Late intraperitoneal injection of dexmedetomedine and bupivacaine
Study: NCT05430945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA Targeted CAR T-cells
Description: Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
Study: NCT06115304

Intervention type: OTHER
Group type: OTHER
Intervention: Large liquid meal, spinal catheter and venous line
Description: Large liquid meal (e.g. Nutricia® Energy 500 ml (750 kcal) admixed paracetamol 1000 mg (for estimation of gastric emptying).~Spinal catheter for 4 hours, with samples taken at one hour interval.~2 venous lines, one for saline and one for venous sampling every half hour
Study: NCT04882943

Intervention type: OTHER
Intervention: questionnaires
Description: Quality of life questionnaires
Study: NCT05994352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality simulation
Description: The effect of virtual reality simulation on therapeutic communication skill levels
Study: NCT05290532

Intervention type: OTHER
Group type: OTHER
Intervention: Individualized exercise training
Description: The intervention will consist of a multicomponent exercise training program, which will composed of supervised progressive resistance exercise training, aerobic and anaerobic exercises. This training period consist on 2 training sessions of 40 minutes (Warm up 5´+ aerobic exercise 15´+ anaerobic exercise 15´+ stretching 5´)per week during 4 weeks after one week of discharge
Study: NCT05181228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Education Based on Family-Centered Empowerment Model
Description: Parents in the intervention group will receive care for ten weeks using the family-centered empowerment model (FCEM). The first step (two weeks) is to increase knowledge. For this purpose, they will receive web-based training on cancer. The second step (four weeks) is to develop parents' self-efficacy and problem-solving skills. A web-based training and group meeting will be held to share information and experiences on the evaluation and control of the side effects of the treatment and to increase their self-efficacy in care. The third step (three week) was to increase self-esteem through participation in the training. At this stage, each participant will be asked to teach one of the family members responsible for the child's care what they have learned in the last two sessions. In the fourth step (one week), all participants in the intervention group will be evaluated by asking questions about the topics discussed in the second and third sessions and the overall content taught.
Study: NCT05165082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% ophthalmic solution
Description: Apply on affected finger or toes twice daily for 8 weeks

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cryotherapy with liquid nitrogen
Description: Conducted on affected finger or toes every other week for four sessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy with liquid nitrogen
Description: Conducted on affected finger or toes every other week for four sessions.
Study: NCT04895475

Intervention type: BEHAVIORAL
Intervention: SARS-CoV-2 vaccine
Description: Baseline demographics, baseline breast milk samples, and blood collection will be obtained at the initial visit. Serial collections of breastmilk and blood as well as weekly self-administered monthly surveys will occur
Study: NCT04949035

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of mental state and quality of life
Description: Patients qualified for rehabilitation will be assessed for stress levels as well as symptoms of anxiety and depression and quality of life before rehabilitation began
Study: NCT05031390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led training
Description: Patients will undergo a 12-week physiotherapist-led training program consisting of 8 supervised sessions and home-based training in between
Study: NCT05568264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy intervention
Description: The intervention is based on five principles: active learning, caregiver engagement, environmental enrichment, strengths-based approach, and dose. The intervention will start in the NICU and continue until 12-months corrected age. Infants in the intervention group will receive up to two therapist visits per week in addition to standard of care physical therapy. Caregivers will be asked to work with their infant on activities provided by the therapist. The therapist will provide resources to support the caregiver in working on these activities with their child, and caregivers will be asked to complete the activities for as much time as possible, throughout the day. Therapists will work with caregivers to identify ways to incorporate activities into their day. Caregiver engagement and caregiver ability to complete sessions and activity recommendations will be monitored.
Study: NCT04906161

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D and calcium levels
Description: Mini VIDAS® compact multiparametric immunoanalyzer for vitamin D analysis (BIOMERIEUX- France)

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D and calcium levels
Description: Mini VIDAS® compact multiparametric immunoanalyzer for vitamin D analysis (BIOMERIEUX- France)
Study: NCT05325853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-920
Description: AG-920 Sterile Topical Ophthalmic Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proparacaine Ophthalmic
Description: 0.5% Proparacaine Hydrochloride
Study: NCT05786898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEAR-TSA
Description: Neuropsychological and Educational Approach of Cognitive Remediation adapted to autism~32 sessions spread over 4 to 8 months (1 session per week for minors, 2 sessions per week for adults), lasting 90 to 120 minutes
Study: NCT06258031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin (COMP360)
Description: Up to 10mg on two occasions
Study: NCT06014827

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo BgRT/SBRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study
Study: NCT04871750

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein
Description: Daily consumption for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Casein protein
Description: Daily consumption for 24 weeks
Study: NCT05274217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Journey of Transformation-Native Youth Health Leadership Program curriculum
Description: Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Journey of Transformation-Native Youth Health Leadership Program curriculum
Description: Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
Study: NCT05270993

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Centre-based Cardiac Rehabilitation (CBCR) group
Description: A 4-week centre-based outpatient cardiac rehabilitation programme where patients will receive 12 group-based sessions. Patients will also be given access to online educational resources. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
Study: NCT05674357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Evidence-Based Therapy in Cancer (Patients)
Description: The intervention will mirror clinical care in psycho-oncology in which the therapist, collaboratively with their supervisor, will choose specific components of the following evidence-based treatments to administer based on the clinical presentation of the patient and referring problem.~* Cognitive Behavioral Therapy (CBT)~* Acceptance Commitment Therapy (ACT)~* Mindfulness-Based Cognitive Therapy (MBCT)~* Mindfulness-Based Stress Reduction (MBSR)~* Meaning-Centered Psychotherapy (MCP)~* Cognitive Behavioral Therapy for Insomnia (CBT-I)~* CBT for pain~* CBT for fatigue~* CBT for nausea

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in Individualized Evidence-Based Therapy in Cancer (Therapists)
Description: Enrolled therapist participants will receive training in evidence-based therapies and deliver therapy to patient participants.
Study: NCT05887219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid
Description: Group A was managed with 4% hydroquinone cream as an adjuvant to oral tranexamic acid (250 mg twice daily) for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B Azelaic Acid 20 % Cream for 6 months
Description: Group B was managed with topical 20% azelaic acid (daily at night) for six months.
Study: NCT05142111

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Discussion with therapist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Discussion with therapist
Study: NCT05230420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clamping
Description: Clamping of chest tube

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urine bag
Description: Attachment of a urine bag to chest tube
Study: NCT05399732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luspatercept
Description: Patients in each group will be treated for at least 6 months and continue the treatment for an additional 6 months unless disease progress or have intolerable side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Patients in each group will be treated for at least 6 months and continue the treatment for an additional 6 months unless disease progress or have intolerable side effects.
Study: NCT06534710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electronic moxibustion apparatus
Description: The experimental group used the electronic moxibustion instrument every day on the basis of the control group
Study: NCT05335382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Interventions (BI)
Description: 'Brief Interventions' (BI) is a multitude of interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. The interventions within BI often have their foundation in CBT, ACT or Motivational Interviewing (MI), however interventions from other schools of therapy can also be used. The common theme is that they are principle-based rather than manual-based and focus on behavioural change in relation to a problem, rather than focusing on a specific diagnosis. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. A BI treatment usually consists of 1-4 appointments with several weeks apart and has an open ending, where the patient easily can schedule a new appointment. Clinicians delivering brief interventions will have had 3 days of training as well as regular supervision.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care As Usual (CAU)
Description: Care As Usual includes the PCC's current routine care for patients with mental and behavioral problems. This can include a multitude of procedures and treatment, such as pharmacological treatment, supportive care, cognitive behavioural therapy (CBT) and psychodynamic therapy of varying lengths. Interviews with patients as well as medical journals will be used to categorise what type of care each individual patient has received.
Study: NCT05647070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous rectus Fascia TOT
Description: A sterile Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through Pfannestiel incision, \~1 cm× \~5 cm rectus fascia strip is isolated from the anterior rectus sheath. Two stay sutures are secured to the corner of the fascial segment on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration
Study: NCT06047522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Casque Lumeen
Description: Participants will take part in virtual reality sessions via headset. They will benefit from a before/after evaluation, and a 3-week intervention where they will have 1 virtual reality session per week.
Study: NCT06325761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5007
Description: SY-5007 160 mg, Tablets, 2 discrete single doses separated by 7-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5007
Description: SY-5007 160 mg, Tablets, 2 discrete single doses separated by 7-days
Study: NCT05824546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention Arm (uSINE-PAMS-technique)
Description: Patients will be lying in a lateral recumbent position and in a fetal position with the neck, back and limbs held in flexion. L3-L4 inter-vertebral space will be identified by palpation of external landmarks of the patients' iliac crests and spinous process of lumbar vertebrae L3, L4 and L5 and confirmed using uSINE-integrated ultrasound. The angle of needle during needle advancement will also be determined using the uSINE-integrated ultrasound. Markings on the patients' skin surface will be made using PAMS (non-sterile component) to enable relocation of the site and angle of the needle entry. Patients' back will be cleaned and draped using aseptic technique. Next, local anaesthesia is infiltrated into the previously identified needle entry site before the LP needle is inserted with location and angulation according to PAMS (sterile component) guidance.
Study: NCT05312710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-157
Description: Treatment